JP2018503611A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503611A5
JP2018503611A5 JP2017532722A JP2017532722A JP2018503611A5 JP 2018503611 A5 JP2018503611 A5 JP 2018503611A5 JP 2017532722 A JP2017532722 A JP 2017532722A JP 2017532722 A JP2017532722 A JP 2017532722A JP 2018503611 A5 JP2018503611 A5 JP 2018503611A5
Authority
JP
Japan
Prior art keywords
sodium
sustained
lactide
poly
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017532722A
Other languages
English (en)
Japanese (ja)
Other versions
JP6606183B2 (ja
JP2018503611A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/066396 external-priority patent/WO2016100677A2/en
Publication of JP2018503611A publication Critical patent/JP2018503611A/ja
Publication of JP2018503611A5 publication Critical patent/JP2018503611A5/ja
Application granted granted Critical
Publication of JP6606183B2 publication Critical patent/JP6606183B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017532722A 2014-12-18 2015-12-17 トロポミオシン関連キナーゼ(trk)阻害剤の医薬製剤 Active JP6606183B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093801P 2014-12-18 2014-12-18
US62/093,801 2014-12-18
PCT/US2015/066396 WO2016100677A2 (en) 2014-12-18 2015-12-17 Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors

Publications (3)

Publication Number Publication Date
JP2018503611A JP2018503611A (ja) 2018-02-08
JP2018503611A5 true JP2018503611A5 (enExample) 2019-01-24
JP6606183B2 JP6606183B2 (ja) 2019-11-13

Family

ID=55080206

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017532722A Active JP6606183B2 (ja) 2014-12-18 2015-12-17 トロポミオシン関連キナーゼ(trk)阻害剤の医薬製剤

Country Status (22)

Country Link
US (4) US10219998B2 (enExample)
EP (1) EP3233057A2 (enExample)
JP (1) JP6606183B2 (enExample)
KR (1) KR102561692B1 (enExample)
CN (2) CN107231803B (enExample)
AR (1) AR103176A1 (enExample)
AU (1) AU2015364557C1 (enExample)
BR (1) BR112017012566B1 (enExample)
CA (1) CA2970938C (enExample)
CL (1) CL2017001543A1 (enExample)
CO (1) CO2017007118A2 (enExample)
EA (1) EA201791336A1 (enExample)
IL (1) IL252901B (enExample)
MA (1) MA40698A3 (enExample)
MX (2) MX387694B (enExample)
MY (1) MY195799A (enExample)
NZ (1) NZ733825A (enExample)
PH (1) PH12017501121B1 (enExample)
SG (1) SG11201704872RA (enExample)
TN (1) TN2017000234A1 (enExample)
TW (2) TWI696621B (enExample)
WO (1) WO2016100677A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663159B (zh) 2013-12-10 2019-06-21 美商健臻公司 原肌球蛋白相關之激酶(trk)抑制劑
EP3233057A2 (en) 2014-12-18 2017-10-25 Genzyme Corporation Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
CN107922396B (zh) 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
CN110156813B (zh) * 2018-02-13 2023-07-25 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
EP4180428A1 (en) * 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
EP4463169A4 (en) * 2022-01-14 2025-10-29 Dimerix Bioscience Pty Ltd COMPOSITIONS COMPRISING A CHEMOKIN RECEPTOR PATHWAY INHIBITOR
CN114712365B (zh) * 2022-06-07 2022-08-23 山东绿叶制药有限公司 Trk抑制剂在制备治疗迟发性运动障碍药物中的应用
WO2024238957A1 (en) * 2023-05-17 2024-11-21 Centrexion Therapeutics Corporation PARTICLES OF IMIDAZO [4,5-b] PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60158180A (ja) 1984-01-30 1985-08-19 Sumitomo Chem Co Ltd ベンズイミダゾ−ル誘導体、その製造法およびそれを有効成分とする殺虫、殺ダニ剤
US4612323A (en) 1983-06-27 1986-09-16 Sumitomo Chemical Company, Limited Insecticidal and acaricidal derivatives of 1-benzylbenzimidazole
JPS6117569A (ja) 1984-07-03 1986-01-25 Sumitomo Chem Co Ltd ベンズイミダゾ−ル誘導体およびそれを有効成分とする殺ダニ剤
JPS6117569U (ja) 1984-07-05 1986-02-01 エヌオーケー株式会社 バルブ装置
JPS61151176A (ja) 1984-12-24 1986-07-09 Sumitomo Chem Co Ltd ベンズイミダゾール誘導体およびそれを有効成分とする殺虫、殺ダニ剤
DE4219534A1 (de) 1992-02-19 1993-12-16 Thomae Gmbh Dr K Substituierte Biphenylylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK154092D0 (da) 1992-12-23 1992-12-23 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
RU2199532C2 (ru) 1997-06-27 2003-02-27 Фудзисава Фармасьютикал Ко., Лтд. Сульфонамидное соединение
JP2002507996A (ja) 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
NZ531153A (en) 2001-08-09 2005-10-28 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
GB0122190D0 (en) 2001-09-14 2001-10-31 Qinetiq Ltd Novel compounds
US20040002145A1 (en) 2002-03-18 2004-01-01 Shewchuk Lisa Marie Crystal structure of liganded cFMS kinase domain
AU2003273179A1 (en) 2002-05-10 2003-12-12 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
CA2560005A1 (en) 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. Phenol derivative, medicinal composition containing the same, and medicinal use thereof
PL1747210T3 (pl) 2004-05-07 2010-11-30 Warner Lambert Co Pochodne 3- lub 4-monopodstawionego fenolu i tiofenolu użyteczne jako ligandy H3
CA2587566A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
PT1853588E (pt) 2005-02-16 2008-08-25 Astrazeneca Ab Compostos químicos
JP2006273879A (ja) 2005-03-25 2006-10-12 Fuji Photo Film Co Ltd カラー表示素子及びカラー表示方法
CA2623958C (en) 2005-09-30 2013-05-28 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted indole derivative
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
EP2139478A4 (en) 2007-03-30 2010-05-05 Cytokinetics Inc CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
SI2493895T1 (sl) 2009-10-29 2017-10-30 Vectura Limited Derivati heteroarila, ki vsebujejo N, kot inhibitorji JAK3 kinaze
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
EP2499117B1 (en) 2009-11-12 2015-10-21 Selvita S.A. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
CA2803448A1 (en) 2010-07-06 2012-01-12 Universite De Montreal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
CN103534257A (zh) 2011-04-05 2014-01-22 辉瑞有限公司 作为原肌球蛋白相关激酶抑制剂的吡咯并[2,3-d]嘧啶衍生物
BR112014014276A2 (pt) 2011-12-12 2017-06-13 Dr Reddys Laboratories Ltd composto, composição farmacêutica, método para inibir uma cinase receptora, e, métodos para tratar condições, doenças e/ou distúrbios, e dor
US9181261B2 (en) * 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
JP6117569B2 (ja) 2013-02-28 2017-04-19 三甲株式会社 ボックスパレット
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
TWI663159B (zh) * 2013-12-10 2019-06-21 美商健臻公司 原肌球蛋白相關之激酶(trk)抑制劑
EP3233057A2 (en) 2014-12-18 2017-10-25 Genzyme Corporation Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
CN107197528B (zh) 2016-03-14 2020-12-25 华为技术有限公司 一种资源调度和分配的方法和装置

Similar Documents

Publication Publication Date Title
EP2528594B1 (en) Effervescent formulations comprising second generation cephalosporin
JP2018517718A5 (enExample)
US11266649B2 (en) Pharmaceutical formulations
TW201322979A (zh) 醫藥組成物
JP5775085B2 (ja) c−METキナーゼ阻害剤の製剤
JP2018503611A (ja) トロポミオシン関連キナーゼ(trk)阻害剤の医薬製剤
WO2011142731A2 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
JP2007197357A5 (enExample)
WO2005082330A2 (en) Co-precipitated amorphous cefditoren pivoxil and dosage forms comprising the same
JP2008500287A5 (enExample)
WO2011093828A2 (en) Solid dosage forms comprising cefprozil
WO2013151518A1 (en) Capsule formulations comprising ceftibuten
EP2515850B1 (en) Pharmaceutical compositions comprising cefdinir as an active agent
WO2012060786A2 (en) Cefpodoxime proxetil formulations comprising viscosity agent
EP2608776A2 (en) Cefpodoxime proxetil formulations
WO2011129792A1 (en) Water dispersible formulations comprising cefpodoxime proxetil
EP2566451B1 (en) Pharmaceutical compositions comprising cefditoren pivoxil
EP2566449A2 (en) Pharmaceutical compositions comprising ceftibuten
EP2515858A1 (en) Pharmaceutical composition with high purity
JP2006298811A (ja) ゲル化抑制製剤の設計
WO2012060787A1 (en) Oral dosage forms comprising cefdinir and carboxymethyl cellulose calcium
CN114173786A (zh) 包含hmg-辅酶a还原酶抑制剂和非诺贝特的药物组合物
EP2566450A2 (en) Pharmaceutical compositions comprising cefetamet
EP2575777A1 (en) Formulation comprising cefpodoxime proxetil and clavulanic acid
WO2011152805A2 (en) Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid